reported that first-line benmelstobart (anti-PD-L1) combined with anlotinib and etoposide/carboplatin (Anl/Ben/CT) significantly prolonged median OS compared with chemotherapy alone (19.3 vs 11.9 months; HR = 0.61; P = 0.0002), highlighting the potential of anti-angiogenic plus immunotherapy combinations in ES-SCLC in the phase III ETER701 trial (27, 132). Here, CD274 is linked to small cell lung carcinoma.